During the past decade, Scranton Hematology Oncology conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 68 clinical trials were completed, i.e. on average, 755.6% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 20 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Scranton Hematology Oncology" #1 sponsor was "National Cancer Institute (NCI)" with 39 trials, followed by "SWOG Cancer Research Network" with 11 trials sponsored, "Eastern Cooperative Oncology Group" with 10 trials sponsored, "Alliance for Clinical Trials in Oncology" with 9 trials sponsored and "NSABP Foundation Inc" with 9 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Scranton Hematology Oncology" #1 collaborator was "National Cancer Institute (NCI)" with 47 trials as a collaborator, "NCIC Clinical Trials Group" with 12 trials as a collaborator, "Cancer and Leukemia Group B" with 10 trials as a collaborator, "SWOG Cancer Research Network" with 8 trials as a collaborator and "North Central Cancer Treatment Group" with 7 trials as a collaborator. Other collaborators include 48 different institutions and companies that were collaborators in the rest 41 trials.

According to Clinical.Site data, the most researched conditions in "Scranton Hematology Oncology" are "Breast Cancer" (17 trials), "Colorectal Cancer" (9 trials), "Lung Cancer" (6 trials), "Lymphoma" (5 trials) and "Recurrent Breast Carcinoma" (5 trials). Many other conditions were trialed in "Scranton Hematology Oncology" in a lesser frequency.

Most popular intervention types in "Scranton Hematology Oncology" are "Drug" (98 trials), "Biological" (49 trials), "Other" (41 trials), "Radiation" (14 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (30 trials), "Bevacizumab" (18 trials), "Quality-of-Life Assessment" (15 trials), "Paclitaxel" (14 trials) and "Carboplatin" (12 trials). Other intervention names were less common.

The vast majority of trials in "Scranton Hematology Oncology" are 78 trials for "All" genders, 29 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Scranton Hematology Oncology". undefined are not yet recruiting, 1 are recruiting, 32 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 60 completed trials in Scranton Hematology Oncology, undefined suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Scranton Hematology Oncology, 1 "Phase 1" clinical trials were conducted, 26 "Phase 2" clinical trials and 81 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".